Effects of the COVID-19 Pandemic on Bladder Cancer Diagnosis and Treatment Processes; A Turkish Multicenter Study

Effects of the COVID-19 Pandemic on Bladder Cancer Diagnosis and Treatment Processes; A Turkish Multicenter Study

Objective: The coronavirus disease-2019 (COVID-19) pandemic effect diagnosis and treatment of certain conditions, including bladder cancer (BC). This study aimed to evaluate the effects of the COVID-19 pandemic on BC diagnosis and treatment. Materials and Methods: Following the approval of the ethics committee for the study, data of 869 patients who underwent surgery for BC in the 2-year period between March 1, 2019 and February 28, 2021 were analyzed retrospectively. The number of surgeries performed for BC, the time elapsed between symptoms and diagnosis, the treatments performed, and the operative pathologies were compared before and during the COVID-19 pandemic. Results: During the COVID-19 period, there was a decrease in the total number of BC surgeries compared to the pre-COVID-19 period (p=0.004). It was observed that this decrease was due to a decrease in patients newly diagnosed with BC (p=0.001) as well as the decrease in the number of primary transurethral resection for bladder tumor procedures performed. There was no difference in the tumor stages of the patients at diagnosis (p=0.9). Intracavitary Bacillus Calmette-Guérin therapy use in high-risk non-muscle invasive bladder cancers (NMIBC) patients also decreased (p=0.008) during the pandemic period. It was observed that the time between symptom and diagnosis was longer in MIBC than in NIMBC during both periods (p

___

  • 1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol 2017;71:96-108.
  • 2. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-461.
  • 3. Pang KH, Noon AP. Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer. Transl Androl Urol 2019;8:101-107.
  • 4. Ghandour R, Singla N, Lotan Y. Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer. Trends Cancer 2019;5:426- 439.
  • 5. Murali-Krishnan S, Pang KH, Greco F, Fiori C, Catto JW, Vavassori VL, Esperto F; EAU-ESRU (European Associations of Urology-European Society of Residents Urologist). Bladder-sparing treatment in MIBC: where do we stand? Minerva Urol Nefrol 2019;71:101-112.
  • 6. Director-General W. WHO director-general’s opening remarks at the media briefing on COVID-19. World Health Organization 2020.
  • 7. Ribal MJ, Cornford P, Briganti A, Knoll T, Gravas S, Babjuk M, Harding C, Breda A, Bex A; GORRG Group, Rassweiler JJ, Gözen AS, Pini G, Liatsikos E, Giannarini G, Mottrie A, Subramaniam R, Sofikitis N, Rocco BMC, Xie LP, Witjes JA, Mottet N, Ljungberg B, Rouprêt M, Laguna MP, Salonia A, Bonkat G, Blok BFM, Türk C, Radmayr C, Kitrey ND, Engeler DS, Lumen N, Hakenberg OW, Watkin N, Hamid R, Olsburgh J, Darraugh J, Shepherd R, Smith EJ, Chapple CR, Stenzl A, Van Poppel H, Wirth M, Sønksen J, N’Dow J; EAU Section Offices and the EAU Guidelines Panels. European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. Eur Urol 2020;78:21-28.
  • 8. Esperto F, Pang KH, Albisinni S, Papalia R, Scarpa RM. Bladder Cancer at the time of COVID-19 Outbreak. Int Braz J Urol 2020;46(Suppl 1):62-68.
  • 9. Vigliar E, Cepurnaite R, Alcaraz-Mateos E, Ali SZ, Baloch ZW, Bellevicine C, Bongiovanni M, Botsun P, Bruzzese D, Bubendorf L, Büttner R, Canberk S, Capitanio A, Casadio C, Cazacu E, Cochand-Priollet B, D’Amuri A, Eloy C, Engels M, Fadda G, Fontanini G, Fulciniti F, Hofman P, Iaccarino A, Ieni A, Jiang XS, Kakudo K, Kern I, Kholova I, Liu C, Lobo A, Lozano MD, Malapelle U, Maleki Z, Michelow P, Musayev J, Özgün G, Oznur M, Peiró Marqués FM, Pisapia P, Poller D, Pyzlak M, Robinson B, Rossi ED, Roy-Chowdhuri S, Saieg M, Savic Prince S, Schmitt FC, Javier Seguí Iváñez F, Štoos-Veić T, Sulaieva O, Sweeney BJ, Tuccari G, van Velthuysen ML, VanderLaan PA, Vielh P, Viola P, Voorham R, Weynand B, Zeppa P, Faquin WC, Pitman MB, Troncone G. Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathol 2020;128:885-894.
  • 10. Dinmohamed AG, Visser O, Verhoeven RHA, Louwman MWJ, van Nederveen FH, Willems SM, Merkx MAW, Lemmens VEPP, Nagtegaal ID, Siesling S. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol 2020;21:750-751.
  • 11. Tulchiner G, Staudacher N, Fritz J, Radmayr C, Culig Z, Horninger W, Pichler R. The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer. Cancers (Basel) 2021;13:1754.
  • 12. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, Ye C, Zhang P, Xing Y, Guo H, Tang W. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020;81:e16-e25.
  • 13. Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970.
  • 14. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-95.
  • 15. Lenfant L, Seisen T, Loriot Y, Rouprêt M. Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic. Eur Urol 2020;78:1-3.
  • 16. Hegarty PK, Kamat AM, Zafirakis H, Dinardo A. BCG vaccination may be protective against Covid-19. preprint 2020;10.
  • 17. Akan S, Ediz C, Kızılkan YE, Alcin A, Tavukcu HH, Yilmaz O. COVID-19 infection threat in patients with high-risk non-muscle invasive bladder cancer receiving intravesical BCG therapy. Int J Clin Pract 2021;75:e13752.
  • 18. Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ. Neoadjuvant Chemotherapy for Muscle- Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist 2016;21:708-715.
  • 19. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
  • 20. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171- 2177.
  • 21. Li G, Niu HM, Wu HT, Lei BY, Wang XH, Guo XB, Feng SL. Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a metaanalysis. Clin Invest Med 2017;40:E81-E94.
  • 22. Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Quevedo FJ, Cheville JC, Karnes RJ. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. Eur Urol Oncol 2019;2:390-396.
Moment Dergi-Cover
  • ISSN: 2148-970X
  • Yayın Aralığı: Yılda 2 Sayı
  • Başlangıç: 2014
  • Yayıncı: Hacettepe Üniversitesi İletişim Fakültesi
Sayıdaki Diğer Makaleler

DİJİTALİN DÖNÜŞTÜRDÜKLERİ: ANALOGDAN DİJİTAL FOTOĞRAFA SÜREKLİLİK VE KOPUŞ

Uğur ÇETİN

MEDYATİK EĞLENCE, DİJİTAL GÖRÜNTÜ, YENİ BELGESEL: 360 DERECE VİDEO ÜZERİNE BİR İNCELEME

Sezer Ahmet KINA

FLÖRT UYGULAMALARINDAKİ İMAJLAR DÜNYASI: “KLİŞELERİN DİKTATÖRLÜĞÜ”NE KARŞI DOĞALLIK

Gözde CÖBEK

The Effect of Transurethral Resection and BCG Therapy on Cytokine Levels in Non-Muscle Invasive Bladder Cancer

Oktay ÜÇER, Gökhan TEMELTAŞ, Talha MÜEZZİNOĞLU, Zeki ARI, Funda KOSOVA

SANATIN YENİ TEKNOLOJİSİ: NFT ÖZGÜN VE ÖZGÜR MÜ?

Özge CENGİZ, Can CENGİZ

Effects of the COVID-19 Pandemic on Bladder Cancer Diagnosis and Treatment Processes; A Turkish Multicenter Study

Ünal ÖZTEKİN, Cemil BAYRAKTAR, Abdullah GÜREL, Burhan BAYLAN, İbrahim KELEŞ, Arif DEMİRBAŞ, Mustafa KARALAR, Osman GERÇEK, Ata ÖZEN, İsmail ULUS, Salih Zeki SÖNMEZ, Erol ERŞEKERCİ, Ali ÇİFT, Ahmet Emin DOĞAN, Berk Yasin EKENCİ, Mert Ali KARADAĞ

İNSANSIZ HAVA ARACI GÖRÜNTÜLERİ VE BARIŞ GAZETECİLİĞİ: İKİNCİ KARABAĞ SAVAŞI ÖRNEĞİ

Can ERTUNA

WALTER BENJAMIN NFT'LERE TANIKLIK ETSEYDİ: KRİPTO SANATA ONUN GÖZÜNDEN BAKMAK

Esra BOZKANAT

ESKİ BİR FOTOĞRAFIN PEŞİNDE KENTİN OTOETNOGRAFİK İZİNİ SÜRMEK: YENİDEN FOTOĞRAFLANAN ÇUKURÇARŞI’DAN GERİYE KALANLAR

Gülbin ÖZDAMAR AKARÇAY

HAMAM, ZENNE, VE YAŞAMIN KIYISINDA FİLMLERİNDE ORYANTALİST İMGELEM VE BAKIŞ

Zeynep ÖZARSLAN, Sanem PEKER DAĞLI